切除修复交叉互补族6-样表达与非小细胞肺癌临床病理特征的关系及其预后意义  

The correlation between ERCC6L expression and clinicopathological characteristics and its prognostic significance in non-small cell lung cancer

作　　者：仇睿[1] 刘阳[1] 马波 吕志平 马云帆[1] QIU Rui;LIU Yang;MA Bo;LYU Zhiping;MA Yunfan(Department of General Thoracic Surgery,Ningxia Medical University General Hospital,Yinchuan 750000,China)

机构地区：[1]宁夏医科大学总医院普胸外科,银川750000

出　　处：《临床外科杂志》2025年第3期266-270,共5页Journal of Clinical Surgery

基　　金：宁夏回族自治区自然科学项目(2021AAC03328)。

摘　　要：目的探讨切除修复交叉互补族6-样(Excision repair cross-complementation group 6-like,ERCC6L)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达特点及其预后价值。方法2016年9月~2019年收治的NSCLC组织及其癌旁组织(距癌组织至少5 cm远的非肿瘤组织)144例,采用免疫组织化学(Immunohistochemistry,IHC)法检测ERCC6L蛋白在NSCLC组织及其癌旁组织中的表达。比较ERCC6L高、低表达病人的临床病理资料,生存分析采用Kaplan-Meier曲线和Cox风险比例回归模型,评估ERCC6L表达与NSCLC病人总体生存(overall survival,OS)的关系。结果IHC染色在42.4%(61/144)的NSCLC组织中检测到ERCC6L高表达,高于癌旁组织(37.7,%,37/144),差异有统计学意义(χ^(2)=8.909,P<0.05)。ERCC6L高表达在低分化癌(χ^(2)=38.660,P<0.001)、T2/T3期(χ^(2)=6.528,P=0.011)和TNMⅢ期肿瘤(χ^(2)=12.522,P<0.05)中更为常见,且淋巴结转移(χ^(2)=5.802,P<0.05)、淋巴血管侵犯(χ^(2)=29.899,P<0.05)与胸膜侵犯(χ^(2)=7.942,P<0.05)较低表达者更为频繁,差异有统计学意义(P<0.05)。生存分析显示与低表达组比较,ERCC6L高表达病人的OS明显更短,5年OS率分别为44.8%和70.5%,差异有统计学意义(χ^(2)=15.919,P<0.05)。单、多变量Cox回归分析表明,ERCC6L高表达(HR=2.106,95%CI=1.087~4.079,P<0.05)是NSCLC病人的独立预后因素。结论ERCC6L在NSCLC中的高表达与肿瘤侵袭性特征密切相关,或许是NSCLC病人一项有价值的预后分子标志物。Objective To investigate the expression of Excision repair cross-complementation group 6-like(ERCC6L)in non-small cell lung cancer(NSCLC),and evaluate its prognostic value.Methods From September 2016 to 2019,144 cases of NSCLC tissues and adjacent tissues(non-tumor tissues at least 5 cm away from cancerous tissues)were admitted.The expression of ERCC6L protein in NSCLC tissues and their adjacent tissues were detected using immunohistochemistry(IHC)method.The clinicopathological data of patients with high and low expression of ERCC6L were compared,and the Kaplan-Meier curves and Cox proportional hazards regression model were used to evaluate the relationship between ERCC6L expression and overall survival(OS)of NSCLC patients.Results The data of IHC staining showed that high expression of ERCC6L was detected in 42.4%(61/144)of NSCLC tissues,which was higher than in their adjacent tissues(37.7,%,37/144)(χ^(2)=8.909,P<0.05).High expression of ERCC6L was frequently detected in poorly differentiated carcinoma(χ^(2)=38.660,P<0.001),T2/T3 stage(χ^(2)=6.528,P=0.011)and TNM stageⅢ(χ^(2)=12.522,P<0.05).In addition,patients with high expression of ERCC6L had higher rates of lymph node metastasis(χ^(2)=5.802,P<0.05),lymphovascular invasion(χ^(2)=29.899,P<0.05)and pleural invasion(χ^(2)=7.942,P<0.05)than those with low expression(P<0.05).Survival analysis revealed that patients with high expression of ERCC6L had a worse prognosis than those with low expression,and the 5-year overall survival(OS)rate of two patient groups was 44.8%and 70.5%,respectively(χ^(2)=15.919,P<0.05).Univariate and multivariate Cox regression analysis demonstrated that high expression of ERCC6L(HR=2.106,95%CI=1.087-4.079,P<0.05)was an independent prognostic factor for NSCLC patients.Conclusion High expression of ERCC6L is closely correlated to tumor aggressive features,and it might be a valuable prognostic biomarker for NSCLC patients.

关 键 词：非小细胞肺癌 切除修复交叉互补族6-样 免疫组织化学 肿瘤侵袭性 预后标志物 

分 类 号：R73[医药卫生—肿瘤]